Company intelligence / Profile preview

Direct Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

ExoFlo™, the lead product, has shown significant survival benefit in a Phase 2 randomized controlled trial for hospitalized COVID-related ARDS. The company also received FDA clearance to initiate clinical trials for ExoFlo™ targeting medically refractory perianal fistulizing Crohn’s Disease. Expanded access programs have surpassed 100 subjects with compelling data reported.

Therapeutic areas: GastroenterologyPulmonologyOther
Modalities: Extracellular Vesicles (EVs) derived from adult human mesenchymal stem/stromal cells
Industry: Biotech

Drug pipeline

1 asset

carmustine

Phase 2

Indications: Brain cancer, Solid tumors

Partnerships

Not explicitly listed. No major pharma or biotech partnerships disclosed on public-facing materials as of May 2025.

Beyond the preview

Go deeper on Direct Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Direct Therapeutics.